AFFINIA THERAPEUTICS Trademark
Trademark Overview
On Tuesday, January 30, 2024, a trademark application was filed for AFFINIA THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the AFFINIA THERAPEUTICS trademark a serial number of 98383240. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Saturday, September 7, 2024. This trademark is owned by Affinia Therapeutics Inc.. The AFFINIA THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:
Adeno-associated virus (AAV) vectors, protein sequences and nucleic acid sequences; Gene therapy products, namely, biopharmaceutical preparations primarily comprised of adeno-associated virus (AAV) vectors comprising a transgene or other nucleic acid payload for delivery to a cell or tissue for the treatment of genetic diseases, conditions and disorders of tissue, organs, muscles, and central nervous system; Biological preparations as therapeutic products for medical use in medical and clinical gene therapy, namely, biological preparations for the treatment of genetic diseases, conditions and disorders of tissue, organs, muscles, and central nervous system; none of the foregoing in the field of analysis and treatment of tumor associated antigens utilizing immune cells
General Information
| Serial Number | 98383240 |
| Word Mark | AFFINIA THERAPEUTICS |
| Filing Date | Tuesday, January 30, 2024 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Saturday, September 7, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Adeno-associated virus (AAV) vectors, protein sequences and nucleic acid sequences; Gene therapy products, namely, biopharmaceutical preparations primarily comprised of adeno-associated virus (AAV) vectors comprising a transgene or other nucleic acid payload for delivery to a cell or tissue for the treatment of genetic diseases, conditions and disorders of tissue, organs, muscles, and central nervous system; Biological preparations as therapeutic products for medical use in medical and clinical gene therapy, namely, biological preparations for the treatment of genetic diseases, conditions and disorders of tissue, organs, muscles, and central nervous system; none of the foregoing in the field of analysis and treatment of tumor associated antigens utilizing immune cells |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 30, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Affinia Therapeutics Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Waltham, MA 02453 |
Trademark Events
| Event Date | Event Description |
| Tuesday, January 30, 2024 | NEW APPLICATION ENTERED |
| Thursday, May 30, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, August 23, 2024 | ASSIGNED TO EXAMINER |
| Saturday, September 7, 2024 | NON-FINAL ACTION E-MAILED |
| Saturday, September 7, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Saturday, September 7, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, December 9, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, December 9, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
